Table 2

Clinical characteristics of the study population (n=201)

Age (years)53.1±13.6
Male128 (63.7%)
Duration of psoriasis (years)26.5±13.5
Duration of PsA (years)18.5±11.1
Duration since first diagnosis of axial involvement (years)9±7.7
Number of swollen joints1.6±3.6
Number of tender and/or swollen joints4.1±7.3
Patients with tender entheseal points29 (14.4%)
Patients with fibromyalgia12 (6%)
ESR (mm/1st h)17.5±17.9
Patients with elevated ESR73 (37%)
CRP (mg/l)12.2±17.3
Patients with elevated CRP43 (30.3%)
Patients global assessment3.3±2.5
Physician global assessment2.2±2.0
BASDAI score3.5±2.4
BASFI score3.1±2.9
Use of NSAIDs110 (54.7%)
Use of DMARDs112 (55.7%)
Use of anti-TNFα agents68 (34%)
HLA-B*27 carriers45 (23%)
Distribution of axial involvement:
 Cervical spine49 (23.6%)
 Thoracic spine47 (24.7%)
 Lumbar spine44 (23.2%)
 Sacroiliitis only111 (58.4%)
  • * 194 patients.

  • 156 patients.

  • ASDAS, Ankylosing Spondylitis Disease Activity Score; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; CRP, C reactive protein; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; NSAIDs, non-steroidal anti-inflammatory drugs; PsA, psoriatic arthritis; TNF, tumour necrosis factor.